Cardiology

Back to articles

A bleak picture of aspirin for primary prevention in older adults

KEY POINT

Three publications in the New England Journal of Medicine from the ASPREE trial showed that daily use of low-dose aspirin in healthy, community-dwelling older people without documented cardiovascular (CV) disease, dementia, or physical disability did not prolong disability-free survival, did not reduce the risk of CV disease (CVD), and was associated with a higher risk of all-cause mortality and major hemorrhage compared with placebo.

SOURCES

McNeil JJ, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;[Epub ahead of print]. 

McNeil JJ, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;[Epub ahead of print]. 

McNeil JJ, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;[Epub ahead of print].